Embecta saw the highest growth of 0.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Embecta’s patent filings and grants. Buy the databook here.
Embecta has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with two publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 100% of filings. The World Intellectual Property Organization(WIPO), and United States(US) patent Office are among the top ten patent offices where Embecta is filings its patents. Among the top granted patent authorities, Embecta has 100% of its grants in United States(US).
Amgen and Becton Dickinson and Co could be the strongest competitors for Embecta
In terms of grant share, Embecta stands in ninth position among its competitors. Amgen and Becton Dickinson and Co secured the top positions according to recent patent publication data.
Drug delivery devices related patents lead Embecta portfolio
Embecta has highest number of patents in drug delivery devices.
For comprehensive analysis of Embecta's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.